Hot Features
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also dev... Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 7.14 | 7.39 | 6.71 | 276128 | 7.04673423 | CS |
| 4 | 0.44 | 6.5671641791 | 6.7 | 8.19 | 6.7 | 365074 | 7.41101907 | CS |
| 12 | 0.33 | 4.84581497797 | 6.81 | 9.58 | 6.58 | 422897 | 7.94023923 | CS |
| 26 | 0.05 | 0.705218617772 | 7.09 | 9.58 | 6.015 | 453027 | 7.49813593 | CS |
| 52 | -5.54 | -43.690851735 | 12.68 | 24.17 | 5.85 | 693213 | 11.59211704 | CS |
| 156 | -18.87 | -72.5490196078 | 26.01 | 45 | 5.85 | 528623 | 18.63874061 | CS |
| 260 | -25.73 | -78.278065105 | 32.87 | 64.9735 | 5.85 | 549741 | 22.91996909 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.